Securities Registration: Employee Benefit Plan (s-8)
31 Mars 2022 - 11:09PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission
on March 31, 2022
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-8
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
Danimer
Scientific, Inc.
(Exact
name of registrant as specified in charter)
Delaware |
|
82-1924518 |
(State
or other jurisdiction
of
incorporation or organization) |
|
(I.R.S.
Employer
Identification
No.) |
140
Industrial Boulevard
Bainbridge,
Georgia |
|
39817 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Danimer
Scientific, Inc. 2020 Long-Term Incentive Plan
Meredian
Holdings Group, Inc. 2016 Director and Executive Officer Stock Incentive Plan,
assumed
by Danimer Scientific, Inc.
Meredian
Holdings Group, Inc. 2016 Omnibus Stock Incentive Plan,
assumed
by Danimer Scientific, Inc.
Novomer,
Inc. 2009 Stock Incentive Plan,
assumed
by Danimer Scientific, Inc.
(Full
title of the plan)
Attn.:
Stephen E. Croskrey
Danimer
Scientific, Inc.
140
Industrial Boulevard
Bainbridge,
Georgia
(Name
and address of agent for service)
Copy
to:
Robert
L. Lawrence, Esq.
Kane
Kessler, P.C.
600
Third Avenue, 35th Floor
New
York, NY 10016
(212)
541-6222
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company”
in Rule 12b-2 of the Exchange Act.
Large accelerated
filer |
☒ |
|
Accelerated
filer |
☐ |
Non-accelerated filer |
☐ |
|
Smaller reporting company |
☐ |
|
|
|
Emerging growth company |
☐ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY
NOTE
Danimer
Scientific, Inc., a Delaware corporation (“Danimer”), has prepared this Registration Statement in accordance with the requirements
of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”). This Registration Statement covers 3,185,362
shares of Class A common stock, $0.0001 par value per share (“Common Stock”), of Danimer Scientific, Inc. (the “Registrant”)
issuable pursuant to the Registrant’s 2020 Long-Term Incentive Plan (the “2020 Incentive Plan”). Under the 2020 Incentive
Plan, the Registrant is issuing up to 2,895,411 shares of Common Stock, which arise from (i) the assumption by the Registrant of the
remaining authorized but unissued shares of common stock underlying the Meredian Holdings Group, Inc. (“MHG”) 2016 Director
and Executive Officer Stock Incentive Plan (adjusted to reflect the merger transaction pursuant to which the Registrant acquired MHG),
and (ii) assumption by the Registrant of the remaining authorized but unissued shares of common stock underlying the MHG 2016 Omnibus
Stock Incentive Plan. Each of the MHG 2016 Director and Executive Officer Stock Incentive Plan and MHG Omnibus Stock Incentive Plan were
approved by MHG’s shareholders upon adoption. Such plans would have expired on May 4, 2026 and awards out of these shares will
not be granted following such date and will otherwise be granted in compliance with New York Stock Exchange (“NYSE”) Rule
303A.08. The Registrant is also issuing under the 2020 Incentive Plan 289,951 shares of Common Stock, which arise from the assumption
by the Registrant of the remaining authorized but unissued shares of common stock underlying the Novomer, Inc. (“Novomer”)
2009 Stock Incentive Plan (adjusted to reflect to the merger transaction pursuant to which the Registrant acquired Novomer). The Novomer
2009 Stock Inventive Plan was approved by Novomer’s shareholders upon adoption. Such plan (as had been amended) would have expired
on July 28, 2024 and awards out of these shares will not be granted following such date and will otherwise be granted in compliance within
NYSE Rule 303A.08. In addition, pursuant to Rule 416 under the Securities Act, this Registration Statement covers an indeterminable
number of additional shares of Common Stock as may hereafter be offered or issued pursuant to the 2020 Incentive Plan to prevent dilution
resulting from stock splits, stock dividends or similar transactions effected without receipt of consideration.
This
Registration Statement also contains information required in the Registration Statement pursuant to Part II of Form S-8 and will be used
for offers or issuances of shares of Common Stock of Danimer pursuant to the 2020 Incentive Plan. The inclusion of such shares herein
does not necessarily represent a present intention to sell any or all such shares of Common Stock.
In
accordance with Instruction E to Form S-8, the contents of the prior Form S-8 registration statement (Commission
File No. 333-254085) is incorporated herein by reference, except for those items being updated by this Registration Statement.
PART
I
INFORMATION
REQUIRED IN THE SECTION 10(a) PROSPECTUS
The
documents containing the information specified in Part I of this Registration Statement will be delivered in accordance with Form S-8 and
Rule 428(d) under the Securities Act of 1933, as amended (the “Securities Act”). These documents are not required to be,
and are not, filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement
or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated
by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute
a prospectus that meets the requirements of Section 10(a) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents filed
with the Securities and Exchange Commission (the “Commission”) by Danimer Scientific, Inc., a Delaware corporation (the “Registrant”),
are incorporated by reference into the Registration Statement:
| ● | the Registrant’s Annual Report on Form 10-K for the year
ended December 31, 2021, as filed with the Commission on March 7, 2022; |
| ● | the
Registrant’s Current Reports on Form 8-K filed with the Commission on January 21, 2022 and February 3, 2022 (in each case, excluding
“furnished” and not “filed” information); and |
| ● | the
description of the Registrant’s Common Stock contained in the Registrant’s registration statement on Form 8-A filed on May
4, 2020, including any amendments or reports filed for the purpose of updating that description. |
All of such documents are
on file with the Commission. In addition, all documents filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act,
subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all the
securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated
by reference in this Registration Statement and are a part hereof from the date of filing of such documents.
Any statement contained in
a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of
this prospectus to the extent that a statement contained herein or in any subsequently filed document that is also incorporated by reference
herein modifies or replaces such statement. Any statements so modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this Registration Statement.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 6. Indemnification of Directors and Officers.
Section 145(a) of the
Delaware General Corporation Law (“DGCL”) provides, in general, that a corporation may indemnify any person who was or is
a party to or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director,
officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees),
judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or
proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests
of the corporation and, with respect to any criminal action or proceeding, had No reasonable cause to believe his or her conduct
was unlawful.
Section 145(b) of the
DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person
is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director,
officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including
attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit
if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation,
except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged
to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that,
despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled
to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper.
Section 145(b) of the
DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person
is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director,
officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including
attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit
if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation,
except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged
to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that,
despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled
to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper.
Section 145(g) of the
DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer,
employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred
by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power
to indemnify the person against such liability under Section 145 of the DGCL.
The Registrant has entered
into indemnification agreements with each of its directors and executive officers. These agreements provide that the Registrant will indemnify
each of its directors and such officers to the fullest extent permitted by law and its charter and its bylaws.
The Registrant also maintains
a general liability insurance policy, which will cover certain liabilities of directors and officers of the Registrant arising out of
claims based on acts or omissions in their capacities as directors or officers.
Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
Exhibit No. |
|
Description |
|
|
|
4.1 |
|
Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K (Commission File No. 001-39280) filed on January 5, 2021). |
|
|
|
4.2 |
|
Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K (Commission File No. 001-39280) filed on February 3, 2022). |
|
|
|
4.3 |
|
Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-236800)). |
|
|
|
4.4 |
|
Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Annex C to the Proxy Statement/Prospectus on Form 424B3 (File No. 333-249691) filed on December 16, 2020). |
|
|
|
4.5 |
|
Form of Stock Option Agreement under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.29 to Current Report on Form 8-K (Commission File No. 001-39280) filed on January 5, 2021).
|
|
|
|
4.6 |
|
Form of Restricted Stock Agreement under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.30 to Current Report on Form 8-K (Commission File No. 001-39280) filed on January 5, 2021). |
|
|
|
4.7 |
|
Meredian Holdings Group, Inc. 2016 Director and Executive Officer Stock Incentive Plan, assumed by Danimer Scientific, Inc. (incorporated by reference to Exhibit 4.8 to Registration Statement on Form S-8 (Commission File No. 333-254085) filed on March 10, 2021). |
|
|
|
4.8 |
|
Meredian Holdings Group, Inc. 2016 Omnibus Stock Incentive Plan, assumed by Danimer Scientific, Inc. (incorporated by reference to Exhibit 4.9 to Registration Statement on Form S-8 (Commission File No. 333-254085) filed on March 10, 2021). |
Item 9. Undertakings
| (a) | The undersigned Registrant hereby undertakes: |
| (1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this
Registration Statement: |
| (i) | to include any prospectus required by Section 10(a)(3) of the Securities Act; |
| (ii) | to reflect in the prospectus any facts or events arising after the effective date of the registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering
price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and |
| (iii) | to include any material information with respect to the plan of distribution not previously disclosed
in the registration statement or any material change to such information in the registration statement; |
provided, however, that paragraphs
(a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act
that are incorporated by reference in the registration statement.
| (2) | that, for the purpose of determining any liability under the Securities Act, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof; and |
| (3) | to remove from registration by means of a post-effective amendment any of the securities being registered
which remain unsold at the termination of the offering. |
| (b) | The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and,
where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is
incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| (c) | Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons of the undersigned Registrant pursuant to the provisions
described in Item 6 or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person
of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled
by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. |
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, as amended, the undersigned registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Bainbridge, State of Georgia, on March 31, 2022.
|
|
DANIMER SCIENTIFIC, INC. |
|
|
|
|
|
By: |
/s/
Stephen E. Croskrey |
|
|
Name: |
Stephen E. Croskrey |
|
|
Title: |
Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE
PRESENTS, that each person whose signature appears below hereby constitutes and appoints Stephen E. Croskrey and Michael A. Hajost, and
each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him
or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments,
to this registration statement on Form S-8, and to file the same, with exhibits thereto and other documents in connection therewith, with
the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to
do and perform each and every act and thing requisite and necessary to be done, as fully for all intents and purposes as he or she might
or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or his or her substitute or
substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements
of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities
and on the date indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Stephen E. Croskrey |
|
Chief Executive Officer, Director and Chairman of the Board |
|
March 31, 2022 |
Stephen E. Croskrey |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Michael A. Hajost |
|
Chief Financial Officer |
|
March 31, 2022 |
Michael A. Hajost |
|
(Principal Financial Officer and Principal Accounting Officer) |
|
|
|
|
|
|
|
/s/ John P. Amboian |
|
Director |
|
March 31, 2022 |
John P. Amboian |
|
|
|
|
|
|
|
|
|
/s/ Richard J. Hendrix |
|
Director |
|
March 31, 2022 |
Richard J. Hendrix |
|
|
|
|
|
|
|
|
|
/s/ Christy Basco |
|
Director |
|
March 31, 2022 |
Christy Basco |
|
|
|
|
|
|
|
|
|
/s/ Philip Gregory Calhoun |
|
Director |
|
March 31, 2022 |
Philip Gregory Calhoun |
|
|
|
|
|
|
|
|
|
/s/ Gregory Hunt |
|
Director |
|
March 31, 2022 |
Gregory Hunt |
|
|
|
|
|
|
|
|
|
/s/ Dr. Isao Noda |
|
Director |
|
March 31, 2022 |
Dr. Isao Noda |
|
|
|
|
|
|
|
|
|
/s/ Stuart Pratt |
|
Director |
|
March 31, 2022 |
Stuart Pratt |
|
|
|
|
II-4
Live Oak Acquisition (NYSE:LOAK)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Live Oak Acquisition (NYSE:LOAK)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024